Clinical Trials

Renal Cell Cancer Trials

Learn More About Our Renal Cell Cancer Trials

  • 1 PCYC-1128-CA Show More

    PCYC-1128-CA – A Phase1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors (Bladder, Colon,Gastric,Renal).

    1. WHAT TYPE OF CANCER? WHAT STAGE?
    Advanced GU Cancer (Bladder and Renal) .

    2. WHO IS ELIGIBLE?
    Advanced GU Cancer (Bladder and Renal) .

    3. HOW WILL I BE TREATED?
    Advanced GU Cancer (Bladder and Renal).

    For Physicians: More information about this specific trial at clinicaltrials.gov

  • 2 EA8143 Show More

    EA8143 – A Phase 3 Randomized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy.

    1. WHAT TYPE OF CANCER? WHAT STAGE?
    Renal Cell Cancer.

    2. WHO IS ELIGIBLE?
    Patients who are to have surgery (disease localized to kidney).

    3. HOW WILL I BE TREATED?
    Nivolumab, an immunotherapy with success in lung and other cancers.

    For Physicians: More information about this specific trial at clinicaltrials.gov

  • 3 CX-839-008 Show More

    CX-839-008 – A Phase III, Randomized,Placebo Controlled Study Of ATEZOLIZUMAB(ANTI-PD-L1 ANTIBODY) As Monotherapy And In Combination With Platinum Chemotherapy In Patients With Untreated Locally Advanced Or Metastatic Urothelial Carcinoma.

    1. WHAT TYPE OF CANCER? WHAT STAGE?
    Renal Cell Cancer.

    2. WHO IS ELIGIBLE?
    Patients with disease progression after first-line therapy.

    3. HOW WILL I BE TREATED?
    Adds CB-839 (a drug that inhibits tumor cell nutrient uptake) to treated with Cabozantinib (a small molecule tyrosine kinase inhibitor).

    For Physicians: More information about this specific trial at clinicaltrials.gov

EJGH Trials Send an Inquiry

Click here